Drug Therapy for Atrial Fibrillation

被引：5

作者：

Conway, Emily L. ^{[1
]}

Musco, Simone ^{[1
]}

Kowey, Peter R. ^{[1
,2
]}

机构：

[1] Lankenau Hosp, Div Cardiovasc Dis, Main Line Heart Ctr, Wynnewood, PA 19096 USA

[2] Thomas Jefferson Univ, Philadelphia, PA 19107 USA

来源：

CARDIOLOGY CLINICS | 2009年 / 27卷 / 01期

关键词：

Atrial fibrillation; Pharmacologic therapy; Rhythm control; Prevention; MAINTAINING SINUS RHYTHM; ANGIOTENSIN-II ANTAGONIST; CONGESTIVE-HEART-FAILURE; N-3; FATTY-ACIDS; ANTIARRHYTHMIC-DRUGS; MYOCARDIAL-INFARCTION; RECEPTOR ANTAGONIST; SUSTAINED-RELEASE; RAPID CONVERSION; CONTROLLED-TRIAL;

D O I：

10.1016/j.ccl.2008.10.003

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Atrial fibrillation is the most frequently diagnosed arrhythmia. Prevalence increases with age, and the overall incidence is expected to increase as the population continues to age. Choice of pharmacologic therapy for atrial fibrillation depends on whether or not the goal of treatment is maintaining sinus rhythm or tolerating atrial fibrillation with adequate control of ventricular rates. Many new antiarrhythmic drugs are currently being tested in clinical trials. Drugs that target remodeling and inflammation have shown potential in prevention of atrial fibrillation, or as adjunctive therapy.

引用

页码：109 / +

页数：16

共 107 条

[41] Increased mortality after dronedarone therapy for severe heart failure [J].

Kober, Lars ;

Torp-Pedersen, Christian ;

McMurray, John J. V. ;

Gotzsche, Ole ;

Levy, Samuel ;

Crijns, Harry ;

Amlie, Jan ;

Carlsen, Jan .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (25) :2678-2687

[42]

KOWEY PR, 2007, CIRCULATION, V114

[43]

KOWEY PR, 2007, HEART RHYTHM, V4, pS72

[44] The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model [J].

Kumagai, K ;

Nakashima, H ;

Saku, K .

CARDIOVASCULAR RESEARCH, 2004, 62 (01) :105-111

[45] Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation [J].

Kumagai, K ;

Nakashima, H ;

Urata, H ;

Gondo, N ;

Arakawa, K ;

Saku, K .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (12) :2197-2204

[46] Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation [J].

L'Allier, PL ;

Ducharme, A ;

Keller, PF ;

Yu, H ;

Guertin, MC ;

Tardif, JC .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 44 (01) :159-164

[47] Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation -: A systematic review of randomized controlled trials [J].

Lafuente-Lafuente, C ;

Mouly, S ;

Longás-Tejero, MA ;

Mahé, I ;

Bergmann, JF .

ARCHIVES OF INTERNAL MEDICINE, 2006, 166 (07) :719-U5

[48] Azimilide vs. placebo and sotalol for persistent atrial fibrillation:: the A-COMET-II (Azimilide-CardiOversion MaintEnance Trial-II) trial [J].

Lombardi, Federico ;

Borggrefe, Martin ;

Ruzyllo, Witold ;

Luederitz, Berndt .

EUROPEAN HEART JOURNAL, 2006, 27 (18) :2224-2231

[49] Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation a prospective and randomized study [J].

Madrid, AH ;

Bueno, MG ;

Rebollo, JMG ;

Marín, I ;

Peña, G ;

Bernal, E ;

Rodriguez, A ;

Cano, L ;

Cano, JM ;

Cabeza, P ;

Moro, C .

CIRCULATION, 2002, 106 (03) :331-336

[50] Valsartan reduces the incidence of atrial fibrillation in patients with heart failure:: Results from the Valsartan Heart Failure Trial (Val-HeFT) [J].

Maggioni, AP ;

Latini, R ;

Carson, PE ;

Singh, SN ;

Barlera, S ;

Glazer, R ;

Masson, S ;

Cerè, E ;

Tognoni, G ;

Cohn, JN .

AMERICAN HEART JOURNAL, 2005, 149 (03) :548-557

← 1 2 3 4 5 6 7 8 9 10 →